KRAS and neoplasm: KRB-456 binds with high affinity to KRAS G12D and KRAS G12V, decreases the cellular levels of GTP-bound KRAS, inhibits the binding of KRAS to RAF1 in pancreatic cancer cells, and inhibits in vivo tumor growth of subcutaneous and orthotopic xenografts from patients with pancreatic cancer.